Pharming Group N.V., of Leiden, the Netherlands, said it has made significant progress with financing toward completion of the transaction with subsidiaries of Valeant Pharmaceuticals International Inc., of Laval, Quebec, to acquire the commercialization rights to its own product Ruconest in North America.